Refine
Has Fulltext
- yes (359)
Is part of the Bibliography
- yes (359)
Year of publication
Document Type
- Journal article (339)
- Doctoral Thesis (19)
- Preprint (1)
Language
- English (359) (remove)
Keywords
- multiple myeloma (33)
- Aspergillus fumigatus (13)
- cancer (10)
- inflammation (10)
- Aspergillus (9)
- T cells (9)
- immunotherapy (9)
- COVID-19 (7)
- apoptosis (7)
- cytokines (7)
- theranostics (7)
- B cells (6)
- CXCR4 (6)
- PET (6)
- Multiple myeloma (5)
- NAFLD (5)
- Positronen-Emissions-Tomografie (5)
- allogeneic stem cell transplantation (5)
- deep learning (5)
- dendritic cells (5)
- neuroendocrine tumor (5)
- Dendritische Zelle (4)
- HIV (4)
- Medizin (4)
- NASH (4)
- PRRT (4)
- SARS-CoV-2 (4)
- endoscopy (4)
- fungal infection (4)
- galactomannan (4)
- immune response (4)
- infection (4)
- invasive pulmonary aspergillosis (4)
- machine learning (4)
- medicine (4)
- prostate cancer (4)
- refractory (4)
- relapse (4)
- stem-cell transplantation (4)
- survival (4)
- therapy (4)
- Bone marrow transplantation (3)
- Candida albicans (3)
- NK cells (3)
- PET/CT (3)
- RADS (3)
- Rheumatoid arthritis (3)
- Rituximab (3)
- SSTR (3)
- Survival (3)
- T cell (3)
- T-cells (3)
- Transplantat-Wirt-Reaktion (3)
- adalimumab (3)
- amyloidosis (3)
- aspergillosis (3)
- automation (3)
- biomarker (3)
- cancer immunotherapy (3)
- cell death (3)
- cell staining (3)
- chimeric antigen receptor (3)
- colonoscopy (3)
- echocardiography (3)
- fatty liver disease (3)
- gastroenterology (3)
- giant cell arteritis (3)
- immune cells (3)
- immunosuppression (3)
- innate immunity (3)
- invasive aspergillosis (3)
- lenalidomide (3)
- memory B cells (3)
- plasma cells (3)
- prognosis (3)
- quality of life (3)
- regression analysis (3)
- rheumatoid arthritis (3)
- scleroderma (3)
- stem cell transplantation (3)
- systemic sclerosis (3)
- toxicity (3)
- 18F-FDG PET/CT (2)
- 3D printing (2)
- AIDS (2)
- AML (2)
- Activation (2)
- Acute myeloid leukemia (2)
- Allogeneic stem cell transplantation (2)
- Autologous hematopoietic stem cell transplantation (2)
- B cell (2)
- BRAF mutation (2)
- Bone-marrow-transplantation (2)
- C-X-C motif chemokine receptor 4 (2)
- CA19-9 (2)
- CADe (2)
- CAR T cell (2)
- CAR T cells (2)
- CCL4 (2)
- CMV (2)
- Cancer (2)
- FDG (2)
- FIB-4 (2)
- FcγR (2)
- GVHD (2)
- German Hepatitis C-Registry (2)
- GvHD (2)
- HBV (2)
- Imatinib (2)
- Immuntherapie (2)
- Natürliche Killerzelle (2)
- PD-L1 (2)
- Rectal cancer (2)
- Ruxolitinib (2)
- Surgery (2)
- Systemic sclerosis (2)
- T-Lymphozyt (2)
- TNF (2)
- TNF receptor superfamily (2)
- Th17 (2)
- Tumor-necrosis-factor (2)
- [68Ga]PentixaFor (2)
- activation (2)
- acute myeloid leukemia (2)
- adaptive immunity (2)
- adverse events (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- anastomotic leakage (2)
- antirheumatic agents (2)
- anxiety (2)
- artificial intelligence (2)
- aspergillus fumigatus (2)
- autologous stem cell transplantation (2)
- beta-D-glucan (2)
- biomarkers (2)
- bone marrow immune-microenvironment (2)
- bortezomib (2)
- cancer microenvironment (2)
- cancer stem cells (2)
- chemokines (2)
- chemotherapy (2)
- cholestasis (2)
- chronic hepatitis C (2)
- chronic kidney disease (2)
- chronic myelogenous leukemia (2)
- corticosteroids (2)
- cytotoxic T cells (2)
- daratumumab (2)
- deformation (2)
- depression (2)
- ejection fraction (2)
- endoluminal (2)
- endoradiotherapy (2)
- endothelial cells (2)
- extramedullary disease (2)
- fatigue (2)
- fibrosis (2)
- fluorescence imaging (2)
- fungal infections (2)
- gastric cancer (2)
- gemcitabine (2)
- gene (2)
- gene expression (2)
- gene regulation (2)
- graft versus host disease (2)
- hematologic malignancies (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- high risk (2)
- ileocecal resection (2)
- immunoassay (2)
- infectious diseases (2)
- invasive fungal infections (2)
- leukemia (2)
- lymphoma (2)
- management (2)
- metabolism (2)
- molecular imaging (2)
- mortality (2)
- mouse model (2)
- mouse models (2)
- murine model (2)
- myeloma (2)
- nab-paclitaxel (2)
- negative pressure (2)
- obesity (2)
- object detection (2)
- oncology (2)
- organoids (2)
- oxidative stress (2)
- paediatric cancer (2)
- pancreatic cancer (2)
- patient-reported outcomes (2)
- peptide receptor radionuclide therapy (2)
- phosphorylation (2)
- platelets (2)
- polymyalgia rheumatica (2)
- pomalidomide (2)
- real world evidence (2)
- real-time PCR (2)
- regulatory T cells (2)
- resistance (2)
- risk factors (2)
- risk stratification (2)
- signal transduction (2)
- sofosbuvir (2)
- somatostatin receptor (2)
- spleen (2)
- surgical therapy (2)
- therapeutic drug monitoring (2)
- translational research (2)
- transplantation (2)
- treatment outcome (2)
- tumour immunology (2)
- vacuum-assisted closure (2)
- 11C-Methionine PET/CT (1)
- 177Lu (1)
- 18FDG-PET/CT (1)
- 2,5-diketopiperazines (1)
- 25-hydroxycholesterol 7 alpha-hydroxylase (1)
- 3 dimensional cell culture model (1)
- 3D culture (1)
- 5-Fluorouracil (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 68Ga-Pentixafor PET/CT (1)
- A. fumigatus (1)
- ABCG2 (1)
- ABL gene (1)
- AKT-signaling (1)
- ALiOS (1)
- AMPK (1)
- APRI (1)
- ARONJ (1)
- ASE formula (1)
- ATPase activity (1)
- ATTRv amyloidosis (1)
- Active disease (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Acute myeloid leukemia (AML) (1)
- Adaptive cell transfer (1)
- Adhesive Hydrogels (1)
- Akt (1)
- Akute myeloische Leukämie (1)
- Alloantigen (1)
- Alloantigen Expression (1)
- Allogeneic transplantation (1)
- Alpelisib (1)
- Alpha therapy (1)
- Alpha-dependent apoptosis (1)
- Amphibia (1)
- Antibodies (1)
- Antikörper (1)
- Apoptosis (1)
- Arthroleptis amphibia (1)
- Arthrose (1)
- Ascaris lumbricoides (1)
- Aspergillus sp. (1)
- Autoimmune diseases (1)
- B cell culture (1)
- B cell receptors (1)
- B-Zellen (1)
- B-cell lymphoma (1)
- B-cells (1)
- B-zellen (1)
- BAL (1)
- BCOR (1)
- BCORL1 (1)
- BH3-only proteins (1)
- BON-1 (1)
- Bacteria (1)
- Bioluminescence (1)
- Bioluminescence imaging (1)
- Biolumineszenzmessung (1)
- Biomarker (1)
- Biomechanics (1)
- Bispecific T-cell engager (1)
- Blood (1)
- Blutstammzelle (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Breath tests (1)
- Bruton's tyrosine kinase inhibitor CC-292 (1)
- Butyrate <Buttersäuresalze> (1)
- C-IAP1 (1)
- C1q/TNF related protein (CTRP) (1)
- C57BL/KALWRIJ mouse (1)
- CACO-2 (1)
- CAPA (1)
- CAR T (1)
- CAR T-cell (1)
- CAR-T-cell (1)
- CASPASE-3 (1)
- CCL3 (1)
- CCL5 (1)
- CCN1 (1)
- CCS (1)
- CD11b+ myeloid cells (1)
- CD1c⁺ mDC (1)
- CD1d (1)
- CD20 (1)
- CD274 (1)
- CD319 (1)
- CD38 (1)
- CD4(+) (1)
- CD4(+) T-cells (1)
- CD40L (1)
- CD95 (1)
- CIAP1 (1)
- CML (1)
- CMR (1)
- CMV reactivation (1)
- CMV-specific cellular immunity (1)
- CNS cancer (1)
- COX2 expression (1)
- CP-690,550 (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CVID (1)
- CXCL10 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Cancer genetics (1)
- Cancer risk factors (1)
- Cancer treatment (1)
- Candida sp. (1)
- Capicua transcriptional repressor (1)
- Cartiage Integration (1)
- Cartilage defect (1)
- Caspase-8 activation (1)
- Cell migration (1)
- Central nervous system (1)
- Central nervous system infection (1)
- Chronic lymphoblastic leukemia (1)
- Chronic myeloid leukaemia (1)
- Chronic myeloid leukemia (1)
- Clinical practice guidelines (1)
- Clinical remission (1)
- Colorectal Cancer (1)
- Complex (1)
- Conditioning regimen (1)
- Copy number changes (1)
- Coronavirus Disease 2019 (1)
- Crohn’s Disease (1)
- Crohn’s disease (1)
- Cytokine (1)
- Cytokine receptors (1)
- D insufficiency (1)
- D serum-levels (1)
- DAS28 (1)
- DC (1)
- DExD/H-Box RNA helicase (1)
- DMARD (1)
- DNA damage (1)
- DOTATOC (1)
- Dara-KDT-P(A)CE (1)
- Darm (1)
- Darmepithel (1)
- Diagnosis (1)
- Dickdarmkrebs (1)
- Donor lymphocytes (1)
- Dopamine (1)
- Drug development (1)
- Drug metabolism (1)
- Drug resistance (1)
- Drug-free remission (1)
- Duchenne muscular dystrophy (1)
- EAE (1)
- EGFR (1)
- EQ5D-5L (1)
- Elderly (1)
- EndoVAC and small bowel (1)
- Enzyme Regulation (1)
- EpCAM (1)
- Epstein-Barr virus-induced gene 2 (1)
- European Society for Immunodeficiencies (ESID) (1)
- European experience (1)
- European experts (1)
- European group (1)
- Expression (1)
- Extramedullary disease (1)
- FDG-PET/CT (1)
- FOLFIRI (1)
- FOLFOX (1)
- FP635 (1)
- Factor receptor (1)
- Fak regulation (1)
- Fludarabine (1)
- Fludarabine-treosulfan (FT) (1)
- Fluoreszenzmikroskopie (1)
- Fluoreszenzproteine (1)
- Fn14 (1)
- Fungal (1)
- Fusarium (1)
- GCA (1)
- GI (1)
- GLP-1 (1)
- GRAID (1)
- GUT-directed hypnotherapy (1)
- GVL (1)
- Gastrointestinal (1)
- Gaussia princeps luciferase (GpL) (1)
- Gelenkknorpel (1)
- Gelenkrheumatismus (1)
- Genetics research (1)
- Genexpression (1)
- German PID-NET registry (1)
- Glucose metabolism (1)
- Glutamate-induced excitotoxicity (1)
- Graft versus Host Disease (1)
- Graft versus Host disease (1)
- Graft versus Tumor (1)
- Graft-versus-host disease (1)
- Graft-versus-leukemia (1)
- Grave’s disease (1)
- Gruppo-italiano (1)
- Guideline (1)
- Guinea pig model (1)
- Guinean rain forest (1)
- HAQ (1)
- HB-EGF (1)
- HCV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HD (1)
- HECT Ligase (1)
- HEV (1)
- HGF (1)
- HIF-1α (1)
- HIV infections (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- HLA antigens (1)
- HLA-E matching (1)
- HNSCC (1)
- HSC (1)
- HSTC outcome (1)
- HT29 cells (1)
- HUWE1 (1)
- Haematology (1)
- Haploidentical (1)
- Hematopoietic Cell Transplantation (1)
- Hematopoietic stem cell transplantation (1)
- Hemibodies (1)
- Hemibody (1)
- Hepatitis B virus (1)
- Hepatitis B virus reactivation (1)
- Hepatitis C (1)
- Hepatitis C infection (1)
- Hepatitis E (1)
- Herpes simplex encephalitis (1)
- Herpes simplex virus (1)
- Hippo signaling (1)
- Hsp90 (1)
- Human immunodefiency virus (1)
- Hyaliner Knorpel (1)
- Hypoxie (1)
- Hämatopoetische Stammzelltransplantation (1)
- Hämostase (1)
- IDO-1 (1)
- IFN-gamma (1)
- IFN-γ ELISpot (1)
- IFNG (1)
- IL-12 family (1)
- IL28B (1)
- IL28B polymorphisms (1)
- IRF4 (1)
- IgG substitution therapy (1)
- Immunantwort (1)
- Immune receptor signaling (1)
- Immunocompromised patient (1)
- Immunologie (1)
- Immunology (1)
- Immunotherapy (1)
- Immunreaktion (1)
- Immunsuppression (1)
- Improved survival (1)
- Induced apoptosis (1)
- Infections (1)
- Infectious Diseases (1)
- Infectious complications (1)
- Infectious disease (1)
- Inflammation (1)
- Influenzae type B (1)
- Interleukin-10 (1)
- Interleukin-2 (1)
- Interleukin-5 (1)
- Intracellular domain (1)
- Invasive Aspergillosis (1)
- Invasive fungal-infections (1)
- JAK2 (1)
- JCV (1)
- Jak kinases (1)
- KRAS (1)
- Kappa-B activation (1)
- Kappa-B pathway (1)
- Killer cell immunoglobulin-like receptors (1)
- Kniegelenkarthrose (1)
- Knorpel (1)
- Kolorektales Karzinom (1)
- Kono-S anastomosis (1)
- LATE DEATHS (1)
- LEOSS (1)
- LINE-1 retrotransposition (1)
- LPS (1)
- Late mortality (1)
- Li-Fraumeni syndrome (1)
- Lichtheimia (1)
- Ligand (1)
- Light Sheet Fluorescence Microscopy (1)
- Lipid metabolism (1)
- Liposomal amphotericin-B (1)
- Liver cirrhosis (1)
- Low-dose acyclovir (1)
- Lymphomas (1)
- M30 (1)
- MAG3 (1)
- MAP-Kinase (1)
- MAPKAPK2 (1)
- MASLD (1)
- MCL-1 (1)
- MDSC (1)
- MEDAS (1)
- MEK/ERK-signaling (1)
- MHC molecules (1)
- MI-RADS (1)
- MIP-1β (1)
- MOPC315.BM (1)
- MOR202 (1)
- MPACT (1)
- MS-18 (1)
- MTB (1)
- MTX (1)
- MUD (1)
- MUST-Score (1)
- MYC (1)
- Malignant melanoma (1)
- Maus (1)
- Mechanisms (1)
- Medicine (1)
- Megakaryozyt (1)
- Melanoma (1)
- Memory B cells (1)
- Mesenchymal stem cells (1)
- Met (1)
- Methotrexate (1)
- Midollo-Osseo (1)
- Migration (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Molecular Biophysics (1)
- Molecularly targeted therapy (1)
- Molekularbiologie (1)
- Monoklonaler bispezifischer Antikörper (1)
- Multiple (1)
- Multiple Myeloma (1)
- Multiples Myelom (1)
- Multivariate analysis (1)
- Mycobacterium avium (1)
- Myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- NA (1)
- NADPH oxidase (1)
- NET (1)
- NF-Kappa-B (1)
- NF-κB/NFAT reporter cells (1)
- NFAT (1)
- NFATc1 (1)
- NFkB (1)
- NFkB-relatedgenes (1)
- NFκB (1)
- NGS (1)
- NK (1)
- NK cell (1)
- NK-DC cross-talk (1)
- NK-cells (1)
- NLRP3 (1)
- NRF2 (1)
- Necrosis (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Neutrophil granulocytes interaction (1)
- Neutrophiler Granulozyt (1)
- OSM (1)
- Oldenburg burnout inventory (1)
- Oncology (1)
- P14ARF (1)
- P67(PHOX) (1)
- PCR (1)
- PHQ-9 (1)
- PID prevalence (1)
- PML (1)
- PMR (1)
- POU6F2-AS2 (1)
- PRO (1)
- PROMISE (1)
- PROM’s (1)
- PSMA (1)
- PSMA-RADS (1)
- PSMC2 (1)
- PU.1 (1)
- Parkinson's disease (1)
- Parkinsons-disease (1)
- Pathogenesis (1)
- Petropedetidae (1)
- Peyer's patch (1)
- Phase- (1)
- Phrynobatrachus amphibia (1)
- Plasmozytom (1)
- Pneumocystis-carinii-pneumonia (1)
- Polymerase chain raction (1)
- Pom‐PAD‐Dara (1)
- Positron emission tomography (1)
- Prediction (1)
- Prodigy (1)
- Prognostic scoring system (1)
- Progressive multifocal leukoencephalopathy (1)
- Pseudomonas aeruginosa (1)
- QGP-1 (1)
- QuantiFERON\(^®\)-TB Gold Plus (1)
- R-CHOP (1)
- RIG-I (1)
- RIP1 (1)
- RNA (1)
- RNA extraction (1)
- RNA sequencing (1)
- ROR1 (1)
- RT-qPCR (1)
- RYGB (1)
- Radiochemotherapy (1)
- Radionuclide Therapy (1)
- Radiotherapy (1)
- Ranidae (1)
- Real-time PCR (1)
- Regulatory-cells (1)
- Respiratory syncytial virus (1)
- Responses (1)
- Rheumatoid Arthritis (1)
- Rheumatoider arthritis (1)
- Rhizopus (1)
- Rhizopus arrhizus (1)
- Risikofaktoren (1)
- Risk factors (1)
- S100A8/S100A9 (1)
- SF-12 (1)
- SF-36 (1)
- SGLT2 inhibitors (1)
- SLAMF7 (1)
- SSTR-RADS (1)
- STAT1 (1)
- STAT3 (1)
- STAT3 activation (1)
- STS (1)
- SVR (1)
- Saccharomyces cerevisiae (1)
- ScFv (1)
- Scleroderma (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Sibling donor (MSD) (1)
- Signal transduction (1)
- Signaling complex (1)
- Signaltransduktion (1)
- Single-chain TNF (1)
- Sjögren’s syndrome (1)
- Skin cancer screening (1)
- Small intestine (1)
- Societe Francaise (1)
- Spleen (1)
- Splicing (1)
- Stage distribution (1)
- Standardisierung (1)
- Stem cell transplantation (1)
- Stimulating factor (1)
- Strategies to Obtain Tumor-Reactive Cells (1)
- Stromal cells (1)
- Structural Biology (1)
- Suppression (1)
- Survival analysis (1)
- Synovitis (1)
- T Zelle (1)
- T-Track\(^®\) TB (1)
- T-cell (1)
- T-cell engager (1)
- T-cell transfer (1)
- TB (1)
- TLR agonists (1)
- TME (1)
- TNF receptor associated factor 2 (TRAF2) (1)
- TNF-related apoptosis-inducing ligand (1)
- TNFR2 (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TNM staging (1)
- TP53 (1)
- TRAF2 (1)
- TRAIL (1)
- TSLP (1)
- TTR knockdown (1)
- TTR stabilization (1)
- TWEAK (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Th17 cells (1)
- Th9 (1)
- Therapy (1)
- Thiotepa-busulfan-fludarabine (TBF) (1)
- Time interval (1)
- Tissue Engineering (1)
- Translational research (1)
- Transport (1)
- Treatment (1)
- Tregs (1)
- Trypanosoma (1)
- Tumorimmunologie (1)
- Tyrosine phosphorylation (1)
- Ubiquitin (1)
- Unrelated donor (UD) (1)
- Upper Guinea (1)
- VAS (1)
- VCE (1)
- VLA-1 (1)
- Validation (1)
- Varicella-Zoster-Virus (1)
- Varicella-zoster-virus (1)
- Viral (1)
- Waldeyer’s tonsillar ring (1)
- Western diet (1)
- Wilms tumor protein 1 (1)
- Wnt (1)
- X-Ray Chrystallography (1)
- YAP (1)
- ZIP (1)
- Zelllysat (1)
- Zellmigration (1)
- Zink (1)
- Zytokin-induzierte Killerzellen (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga] Pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-methionine (1)
- abnormalities (1)
- acoustic radiation force impulse imaging (1)
- actin (1)
- activating receptors (1)
- active TB (1)
- active antiretroviral therapy (1)
- acute Graft versus Host Disease (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute hypobaric hypoxia (1)
- acute kidney injury (1)
- acute leukemia (1)
- acute leukemia (AL) (1)
- acute lymphoblastic leukaemia (1)
- acute lymphoblastic leukemia (1)
- acute myelogenous leukemia (1)
- acute myeloid leukaemia (1)
- acute myeloid-leukemia (1)
- acute respiratory distress syndrome (1)
- adaptive choice-based conjoint (1)
- adenocarcinoma of the ampulla of Vater (1)
- adhesion molecule (1)
- adiponectin (1)
- adjuvant (1)
- adoptive cell therapy (1)
- adoptive transfer (1)
- adrenocortical carcinoma (1)
- adults (1)
- afatinib (1)
- affinity (1)
- africans (1)
- agar diffusion test (1)
- agonism (1)
- agonist (1)
- agonistic antibodies (1)
- all-cause mortality (1)
- alloSCT patients (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alternative to animal testing (1)
- alveolar epithelium (1)
- amphotericin B (1)
- amsacrine (1)
- amyloid‐directed antibodies (1)
- amyotrophic lateral sclerosis (1)
- anaplastic medulloblastoma (1)
- anastomotic leak (1)
- androgen deprivation therapy (1)
- anemia (1)
- animal model (1)
- annotation (1)
- anti-hDEC205-WT1 antibody fusion protein (1)
- anti-infective vaccination (1)
- anti-proliferative effects (1)
- antibody (1)
- anticoagulation (1)
- antifungal (1)
- antifungal agents (1)
- antifungals (1)
- antigen loss (1)
- antigen processing and presentation (1)
- antigen-presenting cells (1)
- antigens (1)
- antileukemia vaccine (1)
- antimicrobial responses (1)
- antimicrobials (1)
- antiphospholipid syndrome (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiretroviral therapy (1)
- antithrombotic therapy (1)
- antiviral treatment (1)
- aplastic anemia (1)
- april (1)
- arthritis (1)
- at-home sampling (1)
- atrial fibrillation (1)
- autoantibodies (1)
- autoimmune disease (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous hematopoietic stem cell transplantation (1)
- autologous transplantation (1)
- autologous tumor (1)
- autophagy (1)
- axi-cel (1)
- axonal transcriptome (1)
- bacterial infection (1)
- beta-oxidation (1)
- bile (1)
- biliary-tract cancer (1)
- binding (1)
- biodiversity (1)
- biodiversity hotspot (1)
- biofilm formation (1)
- biological fluorescence (1)
- bioluminescence imaging (1)
- biomarkers Myelomas (1)
- biophosphonate (1)
- biophysics (1)
- biopsy (1)
- biosynthesis (1)
- bispecific antobodies (1)
- blast cell lysate (1)
- blast-derived RNA (1)
- blinatumomab (1)
- blinatumoman (1)
- blood (1)
- blood flow (1)
- bone (1)
- bone adaptation (1)
- bone disease (1)
- bone imaging (1)
- bone marrow (1)
- bone marrow angiogenesis (1)
- bone marrow cells (1)
- bone marrow failure (1)
- bone marrow homing (1)
- bone marrow transplantation (1)
- bone remineralization (1)
- bone-disease (1)
- bone-mineral density (1)
- bortezomib plus dxamethasone (1)
- brain tumor (1)
- breakpoint (1)
- breakthrough infection (1)
- breast cancer (1)
- bridge-to-transplant (1)
- bridging (1)
- bronchoalveolar lavage fluid (1)
- burnout (1)
- butyrate (1)
- c-reactive protein (1)
- calcium imaging (1)
- calcofluor white staining (1)
- calprotectin (1)
- cancer care (1)
- cancer genomics (1)
- cancer immune cell therapy (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer predisposition (1)
- cancer prevention (1)
- cancer therapy (1)
- cancer treatment (1)
- cancer vaccines (1)
- cancer-induced bone disease (1)
- capture (1)
- carcinoma (1)
- carcinoma cells (1)
- cardiac thrombi (1)
- cardiac transplantation (1)
- care (1)
- carfilzomib (1)
- caspase activation (1)
- caspase-3 (1)
- ceftriaxone (1)
- cell binding (1)
- cell cycle (1)
- cell death and immune response (1)
- cell of origin (1)
- cell therapy and immunotherapy (1)
- cell viability testing (1)
- cell wall (1)
- cellular inhibitor of apoptosis 1/2 (cIAP1/2) (1)
- cereblon expression (1)
- cerebral aspergillosis (1)
- cerebrospinal fluid (1)
- cfRNA (1)
- chemistry (1)
- chemokine receptor (1)
- chenodeoxycholate (1)
- chewed (1)
- children (1)
- cholesterol 25 hydroxylase (1)
- chronic Hepatitis C (1)
- chronic distress (1)
- chronic heart failure (1)
- chronic myeloid leukemia (1)
- chronic phase (1)
- cicatricial pemphigoid (1)
- circulating micrornas (1)
- cirrhosis (1)
- class-I (1)
- clinical imaging (1)
- clinical trial (1)
- clinical-practice (1)
- cluster analysis (1)
- coagulation (1)
- coagulation system (1)
- cognitive hypnotherapy (1)
- cognitive impairment (1)
- collagens (1)
- colorectal cancer (1)
- combination testing (1)
- combination therapy (1)
- commensal bacteria (1)
- common genetic determinants (1)
- common variable immunodeficiency (1)
- common variable immunodeficiency (CVID) (1)
- comorbidities (1)
- comparability (1)
- comparison (1)
- complement system (1)
- complication (1)
- complications (1)
- comprehensive management (1)
- comprehensive psychosomatic assessment (1)
- computed tomography (1)
- consensus statement (1)
- conservation (1)
- contrast-enhanced ultrasound. (1)
- corticosteroids and cyclophosphamide (1)
- critically ill patients (1)
- cyclophosphamide (FLAMSA) (1)
- cytarabine dose (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytogenetic response (1)
- cytogenetics (1)
- cytokine (1)
- cytokine production (1)
- cytokine-induced killer cells (1)
- cytokinesis (1)
- cytopenia (1)
- cytotoxicity (1)
- cytotoxicity receptors (1)
- dabrafenib (1)
- daratumumab monotherapy (1)
- ddPCR (1)
- death rates (1)
- deep metric learning (1)
- definition (1)
- degradation (1)
- deletion 17P (1)
- dendritic cell (1)
- dendritic cell-targeting (1)
- dendritische Zellen (1)
- denritic cells (1)
- derivates (1)
- detoxification (1)
- dexamethasone (1)
- diagnostic medicine (1)
- diagnostics (1)
- different imatinib dose regimens (1)
- differentiated thyroid tumor (1)
- differentiation (1)
- diffuse large B-cell lymphoma (1)
- diffusion weighted mri (1)
- diketopiperazines (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- discharge definition (1)
- discordance (1)
- disease (1)
- disease comorbidities (1)
- disease score (1)
- disease severity (1)
- disease-activity score (1)
- disengagement (1)
- disorder of immunity (1)
- disorders (1)
- dolutegravir (1)
- donor-cell leukemia (1)
- downstream (1)
- drug (1)
- drug adherence (1)
- drug monitoring (1)
- drug resistance (1)
- drug screening (1)
- drug-induced immune hemolytic anemia (1)
- drug–drug interactions (DDIs) (1)
- dual targeting (1)
- duodenal perforation (1)
- duodenal trauma (1)
- early applied higher imatinib dosages (1)
- early detection (1)
- early onset sepsis (1)
- elderly (1)
- elderly patients (1)
- elderly persons (1)
- electrogastrographic egg activities (1)
- elotuzumab (1)
- emtricitabine (1)
- enal impairment (1)
- endoscopic (1)
- endoscopic full thickness resection (eFTR) (1)
- endoscopic instruments (1)
- endoscopic intervention (1)
- endosponge (1)
- engaging aantibody (1)
- engraftment syndrome (1)
- enzyme-linked immunoassays (1)
- epidemiology (1)
- epidemology (1)
- epithelial-mesenchymal transition (1)
- erythropoiesis-stimulating agents (1)
- esophageal perforation (1)
- european leukemia net (1)
- exhaustion (1)
- expression (1)
- extramedullary (1)
- extramedullary hematopoiesis (1)
- familial amyloid polyneuropathy (FAP) (1)
- fatty liver (1)
- fear of progression (1)
- fever (1)
- few-shot learning (1)
- fibrin D-dimer (1)
- fibroblast activation protein (1)
- fibrosis progression (1)
- fibrotest (1)
- fine-needle-aspiration (1)
- fluorescence (1)
- fluorescence in situ hybridization (FISH) (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- folinic acid (1)
- free survival (1)
- full-thickness resection device (FTRD) (1)
- functional abdominal pain (1)
- fungal aerosolization (1)
- fungal disease (1)
- fungal host response (1)
- fungal infection model (1)
- fungal molecular diagnostics (1)
- fungal sinusitis (1)
- fungi (1)
- gRNA-only (1)
- galectin-2 (1)
- gammadelta T cells (1)
- gastric bypass (1)
- gastric emptying (1)
- gastrointestinal dysfunction (1)
- gastrointestinal infections (1)
- gastrointestinal perforation (1)
- gastrointestinal symptoms (1)
- gastrointestinal tract (1)
- gene expression data (1)
- gene regulation in immune cells (1)
- gene therapy (1)
- gene-environment interaction (1)
- genetic polymorphisms (1)
- genetic susceptibility (1)
- genital warts (1)
- genus (1)
- german people (1)
- glecaprevir/pibrentasvir (1)
- glial fibrillary acidic protein (1)
- glioblastoma (1)
- graft-versus-host-disease (1)
- granulocytes (1)
- group 3 (1)
- group consensus statement (1)
- growth differentiation factor 15 (1)
- growth-factor receptor 3 (1)
- growth-factor-receptor (1)
- gut–liver axis (1)
- haematopoietic stem cell (1)
- haploidentical γδ T lymphocytes (1)
- head and neck cancer (1)
- health care (1)
- health-assessment questionnaire (1)
- healthy volunteers (1)
- heart failure (1)
- helicase (1)
- helicobacter pylori infection (1)
- hematological malignancies (1)
- hematology (1)
- hematopoietic (1)
- hematopoietic SCT (1)
- hematopoietic cell transplantation (1)
- hematopoietic stem cell transplantation (HSCT) (1)
- hematopoietic stem cells (1)
- hemodialysis (1)
- hemolysis (1)
- hemolytic anemia (1)
- hepatic stellate cells (1)
- hepatitis B virus (1)
- hepatocellular carcinoma (1)
- high-risk cytogenetics (1)
- high-risk hematology (1)
- highly-active antiretroviral therapy (1)
- homing (1)
- hospitalization (1)
- host defense (1)
- host genetics (1)
- host response (1)
- host-pathogen interaction (1)
- human biomarker (1)
- human cholangiocellular carcinoma (1)
- human cytomegalovirus (HCMV) (1)
- human dendritic cells (1)
- human hepatic cells (1)
- human intrahepatic cholangiocarcinoma (1)
- human leukocyte antigen-E (HLA-E) (1)
- human multiple-myeloma (1)
- human papillomavirus (1)
- human pathogen (1)
- human pathogenic fungi (1)
- humans (1)
- hybrid messenger RNA (1)
- hydroxy-dabrafenib (1)
- hypersensitivity (1)
- hypnotic susceptibility (1)
- hypogammaglobulinemia (1)
- i-131 uptake (1)
- iNKT (1)
- idiotype (1)
- image classification (1)
- imaging the immune system (1)
- immune activation (1)
- immune cell recruitment (1)
- immune control (1)
- immune impairment (1)
- immune modulation (1)
- immune monitoring (1)
- immune receptors (1)
- immune reconstitution (1)
- immune therapy (1)
- immunity (1)
- immuno-oncology (1)
- immunocompromised patients (1)
- immunogenetics (1)
- immunoglobulin rearrangement (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- immunology (1)
- immunophenotyping (1)
- immunosurveillance (1)
- immunotherapeutics (1)
- in vitro Testmodell (1)
- in vitro model (1)
- in vivo cell expansion (1)
- inborn errors of immunity (IEIs) (1)
- incidence (1)
- independent marker (1)
- individual mind state (1)
- individualized surgery (1)
- induce cyclooxygenase-2 expression (1)
- induced apoptosis (1)
- induction regimen (1)
- infection detection (1)
- inflammasome (1)
- inflammation marker (1)
- inflammation-induced tissue demage (1)
- infusion (1)
- inhibition (1)
- inhibitor (1)
- inhibitory receptors (1)
- injury (1)
- innate immune response (1)
- instrument (1)
- insulin (1)
- insulin signaling (1)
- integrase inhibitor (1)
- integrins (1)
- intensity of attention (1)
- interaction (1)
- interacts (1)
- interferon (1)
- interferon alpha (1)
- interferon alpha (IFNα) (1)
- interferon alpha signalling (1)
- interferon gamma (1)
- interferon-alpha (1)
- interferon-free (1)
- intergroupe francophone (1)
- interleukin 1 (1)
- interleukin 18 (1)
- interleukin-6 (1)
- interleukin-9 (1)
- intermediate dose Ara-C (1)
- intervention (1)
- intestinal barrier (1)
- intestinal-type adenocarcinoma (1)
- intestine (1)
- intramolecular Michael addition (1)
- intratumoral microbiota (1)
- invasive candidiasis (1)
- invasive fungal infection (1)
- iohexol (1)
- irinotecan (1)
- iron homeostasis (1)
- irritable-bowle-sondrome (1)
- ischemic stroke (1)
- isoforms (1)
- ivory coast (1)
- janus kinase inhibitor (1)
- keratin-18 (1)
- kidney (1)
- kidney cancer (1)
- kidney function (1)
- kinase inhibitors (1)
- kinease (1)
- kinesin (1)
- laminin 332 (1)
- large B-cell lymphoma (1)
- lasso regression (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lenalidomide-refractory patients (1)
- lentiviral transduction (1)
- lesions (1)
- library screening (1)
- life-threatening side-effects (1)
- lifestyle habits (1)
- ligand incompatibility (1)
- ligand trail (1)
- lineage (1)
- liquid biopsy (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liraglutide (1)
- liver (1)
- liver disease (1)
- liver diseases (1)
- liver fibrosis (1)
- locally advanced disease (1)
- loss-of-function (1)
- low molecular heparin (1)
- lymph node metastases (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte activation (1)
- lymphocytes (1)
- lysine biosynthesis (1)
- mAb engineering (1)
- mRNA (1)
- mRNA-Seq (1)
- mTOR (1)
- magnetic resonance imaging (1)
- malignant transformation (1)
- malnutrition (1)
- mammalian genomics (1)
- mantle cell lymphoma (1)
- marrow plasma cells (1)
- matrix metallopeptidase-1 (1)
- mebendazole (1)
- mechanical loading (1)
- mechanism (1)
- mechanosensing (1)
- mechanotransduction (1)
- megakaryocytes (1)
- melanoma (1)
- melanoma malignancy (1)
- melanoma therapy (1)
- mental impairment (1)
- mesenteric lymph node (1)
- messenger RNA (1)
- metabolic tumor volume (MTV) (1)
- metals (1)
- metastasis (1)
- metastasis-directed therapy (1)
- methionine (1)
- methotrexate (1)
- methylation (1)
- miR-122 (1)
- miR-132 (1)
- miR-146 (1)
- miR-155 (1)
- microRNA (1)
- microbiome (1)
- microbiota-derived metabolites (1)
- micronuclei (1)
- microswimmer (1)
- mindfulness (1)
- minimal residual disease (1)
- minimally important difference (1)
- minimally invasive surgery (1)
- mismatch (1)
- missing self (1)
- mitochondrial DNA (1)
- mixed infection (1)
- modified Rodnan skin score (mRSS) (1)
- mold disease (1)
- mold exposure (1)
- molecular data (1)
- molecular diagnosis (1)
- molecular response in cml (1)
- monoclonal antibody (1)
- monoclonal gammopathy (1)
- monoclonal-antibodies (1)
- monocytes (1)
- motivational level (1)
- mouse feeding model (1)
- mouse models DNA damage (1)
- mtDNA (1)
- mucormycosis (1)
- mucous membrane pemphigoid (1)
- multicomponent Ugi-type reaction (1)
- multimodal (1)
- multiparameter flow-cytometry (1)
- multiparameter flow-cytpmetry (1)
- multiparametric flow cytometry (1)
- multiple myeloma Lesions (1)
- multiplex PCR (1)
- multiplicity of infection (1)
- muscle (1)
- music (1)
- mutation (1)
- mycophenolate (1)
- mycophenolic acid (1)
- mycoses (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- myeloma cells (1)
- myofibroblast (1)
- myokines (1)
- nOAC (1)
- naive T-cell gene editing (1)
- nanoparticle albumin-bound paclitaxel (1)
- natural killer cell (1)
- natural killer cells (1)
- natural language processing (1)
- naïve B cells (1)
- necroptosis (1)
- necrotic cell death (1)
- neoadjuvant (1)
- neoadjuvant chemotherapy (1)
- network (1)
- neuralgic amyotrophy (1)
- neuroendocrine neoplasia (1)
- neuroendocrine tumor (NET) (1)
- neuroimmunology (1)
- neurology (1)
- neutropenic fever (1)
- new species (1)
- newly diagnosed (1)
- newly-diagnosed myeloma (1)
- nichtinvasive Bildgebung (1)
- nicotinamide (1)
- no correlation (1)
- nomogram (1)
- non-alcoholic fatty liver disease (NAFLD) (1)
- non-alcoholic steatohepatitis (NASH) (1)
- non-interventional (1)
- non-invasive fibrosis assessment (1)
- nonalcoholic fatty liver disease (1)
- none (1)
- normal values (1)
- novel therapies (1)
- nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NFκB) (1)
- nuclear receptors (1)
- nucleoside transporter (1)
- nucleotide excision repair (1)
- nutritional counseling (1)
- nutritional medical needs (1)
- nutritional risk screening (1)
- obinutuzumab (1)
- observational (1)
- oesophagogastroduodenoscopy (1)
- older patients (1)
- oligmometastases (1)
- oligorecurrence (1)
- oncobiome (1)
- oncogenesis (1)
- oncologist (1)
- oncology outpatients (1)
- oncostatin M (1)
- ontology (1)
- operating platform (1)
- ophthalmic artery (1)
- optic nerve (1)
- oral anticancer drugs (1)
- oral anticoagulants (1)
- oral microbiome (1)
- orbit (1)
- orthotopic xenograft (1)
- osimertinib (1)
- osteokines adaptation (1)
- osteonecrosis of the jaw (1)
- osteoradionecrosis (1)
- outbreak (1)
- outcomes research (1)
- outreach (1)
- overdose (1)
- oxaliplatin (1)
- p38 MAPK (1)
- p53 (1)
- pan-RCC (1)
- pancreatectomy (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic head cancer (1)
- pancreatic neoplasms (1)
- pancreatobiliary type (1)
- panobinostat (1)
- parasite biology (1)
- participation in clinical trials (1)
- pathogen-associated molecular patterns (1)
- pathogenic TP53 germline variant (1)
- pathophysiology (1)
- pathway (1)
- patient access (1)
- patient preference (1)
- patient-based evidence (1)
- patients with multiple myeloma (1)
- pattern (1)
- pattern recognition receptors (1)
- pediatric (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- peptide (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- personalised medicine (1)
- personalized medicine (1)
- pharmacokinetic (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- pharmacology (1)
- phosphatidyl-inositol-3-kinase p110 alpha (1)
- phosphatidylinositol 3-kinase/Akt (1)
- physical activity (1)
- physicians (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- plasma cell disorder (1)
- plasma clearance (1)
- platelet activation (1)
- platelet aggregation (1)
- plus dexamethasone (1)
- point shear wave elastography (1)
- poly(ADP-ribose) polymerase inhibitors (1)
- polymerase-chain-reaktion (1)
- polyp (1)
- population pharmacokinetics (1)
- population-based cohort (1)
- porcine large animal model (1)
- posaconazole (1)
- positron emission tomography (1)
- positron emission tomography/computed tomography (1)
- postoperative bleeding (1)
- pre-clinical models (1)
- precision medicine (1)
- precision oncology (1)
- prediction (1)
- predictive factor (1)
- predictive markers (1)
- prenatal paternal depression (1)
- preoperative planning (1)
- prevalence (1)
- primary biliary cholangitis (1)
- primary immunodeficiencies (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- primary sclerosing cholangitis (1)
- probe-based real-time PCR (1)
- progression (1)
- prolonged cytopenia (1)
- prophylaxis (1)
- prospective (1)
- prospective feasibility (1)
- prostaglandin E2 (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- proteasome inhibitors (1)
- psoriasis (1)
- psychology (1)
- psychosocial (1)
- public health (1)
- pulmonary aspergillosis (1)
- pulmonary immune response (1)
- radiation therapy (1)
- radiogenomics (1)
- radioligand therapy (1)
- radionuclide therapy (1)
- rainforest (1)
- raltegravir (1)
- randomized controlled trial (1)
- randomized phase-3 trial (1)
- rapid prototyping (1)
- rare SNP (1)
- real life setting (1)
- real time PCR (1)
- real world data (1)
- real-time (1)
- recall antigen (1)
- receptor expression (1)
- receptor tyrosine kinases (1)
- recognition (1)
- recombinant-human-erythropoietin (1)
- rectal sensitivity (1)
- rectum (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- reference data (1)
- region (1)
- registry for primary immunodeficiency (1)
- relapsed (1)
- relapsed and refractory (1)
- relaxation (1)
- renal failure (1)
- renal function (1)
- renal perfusion (1)
- renal scintigraphy (1)
- reported outcomes (1)
- reporting and data systems (1)
- respiratory virus (1)
- resting NK cells (1)
- rheumatoid (1)
- rheumatoid arhritis (1)
- rheumatoide Arthritis (1)
- ribavirin serum levels (1)
- risk factor (1)
- risk pregnancy (1)
- risk factor analysis (1)
- rituximab (1)
- ruxolitinib (1)
- safety (1)
- salt consumption (1)
- salt-intake-related behavior (1)
- salvage (1)
- sarcoma (1)
- scid mice (1)
- screening for distress (1)
- second line therapy (1)
- secondary metabolite gene cluster (1)
- serotonin (1)
- serum biomarkers (1)
- serum creatinine (1)
- serum retention (1)
- severe fibrosis (1)
- signal inhibition (1)
- signaling (1)
- significance MGUS (1)
- silkworm (1)
- sirolimus (1)
- skeletal mechanobiology (1)
- skin equivalents (1)
- sleeping sickness (1)
- slice culture (1)
- small bowel bleeding (1)
- small interfering RNAs (1)
- smoldering multiple-myeloma (1)
- smoldering myeloma (1)
- somatic symptom burden (1)
- somatostatin receptor (SSTR) (1)
- spatial heterogeneity (1)
- stable isotope breath tests (1)
- standardization (1)
- standardized reporting (1)
- steatosis (1)
- steatotic liver disease (1)
- stem cells (1)
- stereotactic body radiotherapy (1)
- stimulation (1)
- strategy (1)
- streptococci (1)
- stress (1)
- stress level (1)
- stromal cells (1)
- structural biology (1)
- subunit (1)
- suicide attempt (1)
- sulfur (1)
- super-resolution microscopy (1)
- superior (1)
- suppression (1)
- surgical care (1)
- surgical manipulator (1)
- susceptibility (1)
- sustained virological response (1)
- symptom burden (1)
- systemic candidiasis (1)
- systemic therapy (1)
- t-lymphocytes (1)
- target validation (1)
- targeted therapies (1)
- targeted therapy (1)
- targeting (1)
- taxonomy (1)
- tenofovir disaproxil fumarate (1)
- term-follow-up (1)
- thalidomide maintenance (1)
- thrombin (1)
- thromboembolism (1)
- thrombopoiesis (1)
- thrombosis (1)
- tissue engineering (1)
- tocilizumab (1)
- tocilizumab (IL-6 inhibitor) (1)
- total body irradiation/busulfan (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- trabectedin (1)
- trail-mediated apoptosis (1)
- trametinib (1)
- transactivation (1)
- transanal endoscopic microsurgery (TEM) (1)
- transcriptome (1)
- transcriptome profiling (1)
- transcriptomics (1)
- transcripts (1)
- transformer (1)
- transient elastography (1)
- transient regulatory T-cell targeting (1)
- translocation (1)
- transporter protein associated with antigen processing-1 (TAP1) (1)
- transstomal endoluminal vacuum therapy (1)
- transthyretin (1)
- treatment response (1)
- trispecific (1)
- tsetse fly (1)
- tuberculosis (1)
- tumor burden (1)
- tumor microenvironment (1)
- tumor microenvironment (TME) (1)
- tumor necrosis factor (TNF) (1)
- tumor specific antigen (1)
- tumor-infiltrating (1)
- tumor-specific CD8+ T cells (1)
- tumormicroenvironment (1)
- tumor‐specific antigen (1)
- tumour-necrosis factors (1)
- tyrosine-kinase inhibitor (1)
- ulcerative colitis (1)
- undetermined significance MGUS (1)
- ursodeoxycholic acid (1)
- validation (1)
- vascularization (1)
- vasculature (1)
- vasculitis (1)
- venetoclax (1)
- venous thromboembolic disease (1)
- verteporfin (1)
- video capsule endoscopy (1)
- video object detection (1)
- viral clearance (1)
- viral infection (1)
- viral load (1)
- viral replication (1)
- virulence (1)
- virus (1)
- virus infection (1)
- virus-infected cells (1)
- virus-specific T-cell (1)
- vitamin D (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- warfarin interruption (1)
- water load test (1)
- weight gain (1)
- whole blood specimens (1)
- whole-body imaging (1)
- yoga (1)
- zinc (1)
- zoledonic acid (1)
- β-catenin (1)
- γδ T cells (1)
Institute
- Medizinische Klinik und Poliklinik II (359) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (3)
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (2)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (1)
- Department of Hematology and Oncology, Sana Hospital Hof, Hof, Germany (1)
- Department of Laboratory Medicine and Medicine Huddinge, Karolinska Institutet and University Hospital, Stockholm, Sweden (1)
- Department of Medicine A, University Hospital of Münster, Münster, Germany (1)
- Interdisciplinary Center for Clinical Research (IZKF), Würzburg, Germany (1)
- Interdisziplinäres Amyloidosezentrum Nordbayern (1)
- Johns Hopkins University School of Medicine (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
ResearcherID
- N-2030-2015 (1)
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE-syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%-subcutaneous; 29%-intravenous; 1%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Background: Non-alcoholic steatohepatitis (NASH) is a chronic liver disease with severe complications and without approved therapies. Currently, there is limited data on the overall burden of the disease for patients or on patient needs and preferences. This study investigates patient preferences in relation to potential future therapies for NASH. In addition, the factors that are relevant to patients and their importance in relation to future treatment options are explored.
Method: Telephone in-depth interviews (TDIs) preceded an online 30-min quantitative survey. The online survey included (1) multiple choice questions (MCQs) on NASH diagnosis and disease background. (2) An exercise to determine patients' satisfaction levels with information provided at diagnosis, and to explore symptomatology in detail. (3) Exercises to evaluate potential new products and product attributes, including a "drag and drop" ranking exercise, and an adaptive choice-based conjoint exercise (ACBC). (4) The EQ-5D-5L questionnaire and the Visual Analog Scale (VAS), which measures patients' health status. (5) Collection of socio-demographic data, and (6) Questions to measure patient satisfaction with the survey.
Results: There were 166 patients included in this study from Canada [n = 36], Germany [n = 50], the UK [n = 30], and USA [n = 50]. Fifty seven percent of patients [n = 94] had had a liver biopsy for confirmation of NASH. Patients were often unable to link their symptoms to NASH or other conditions. ACBC results showed that efficacy, defined as "impact on liver status" was the single most important attribute of a potential future NASH therapy. Other attributes considered to have secondary importance included impact on weight, symptom control and the presence of side effects. The EQ-5D utility score was 0.81 and VAS = 67.2.
Conclusion: "Impact on liver status" is the primary outcome sought. Patients demonstrate a general lack of understanding of their disease and appeared to be unfamiliar with longer-term consequences of NASH. It is necessary to improve patient understanding of NASH and its progressive nature, and there is a need for improving confirmatory diagnosis and monitoring.
In most organisms, ribosomal RNA (rRNA) contributes to >85% of total RNA. Thus, to obtain useful information from RNA-sequencing (RNA-seq) analyses at reasonable sequencing depth, typically, mature polyadenylated transcripts are enriched or rRNA molecules are depleted. Targeted depletion of rRNA is particularly useful when studying transcripts lacking a poly(A) tail, such as some non-coding RNAs (ncRNAs), most bacterial RNAs and partially degraded or immature transcripts. While several commercially available kits allow effective rRNA depletion, their efficiency relies on a high degree of sequence homology between oligonucleotide probes and the target RNA. This restricts the use of such kits to a limited number of organisms with conserved rRNA sequences. In this study we describe the use of biotinylated oligos and streptavidin-coated paramagnetic beads for the efficient and specific depletion of trypanosomal rRNA. Our approach reduces the levels of the most abundant rRNA transcripts to less than 5% with minimal off-target effects. By adjusting the sequence of the oligonucleotide probes, our approach can be used to deplete rRNAs or other abundant transcripts independent of species. Thus, our protocol provides a useful alternative for rRNA removal where enrichment of polyadenylated transcripts is not an option and commercial kits for rRNA are not available.
The pediatric immune deficiency X-linked proliferative disease-2 (XLP-2) is a unique disease, with patients presenting with either hemophagocytic lymphohistiocytosis (HLH) or intestinal bowel disease (IBD). Interestingly, XLP-2 patients display high levels of IL-18 in the serum even while in stable condition, presumably through spontaneous inflammasome activation. Recent data suggests that LPS stimulation can trigger inflammasome activation through a TNFR2/TNF/TNFR1 mediated loop in xiap−/− macrophages. Yet, the direct role TNFR2-specific activation plays in the absence of XIAP is unknown. We found TNFR2-specific activation leads to cell death in xiap−/− myeloid cells, particularly in the absence of the RING domain. RIPK1 kinase activity downstream of TNFR2 resulted in a TNF/TNFR1 cell death, independent of necroptosis. TNFR2-specific activation leads to a similar inflammatory NF-kB driven transcriptional profile as TNFR1 activation with the exception of upregulation of NLRP3 and caspase-11. Activation and upregulation of the canonical inflammasome upon loss of XIAP was mediated by RIPK1 kinase activity and ROS production. While both the inhibition of RIPK1 kinase activity and ROS production reduced cell death, as well as release of IL-1β, the release of IL-18 was not reduced to basal levels. This study supports targeting TNFR2 specifically to reduce IL-18 release in XLP-2 patients and to reduce priming of the inflammasome components.
Background
Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC.
Methods
This prospective, randomised, phase II study investigated the efficacy of catumaxomab followed by chemotherapy (arm A, 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, FLOT) or FLOT alone (arm B) in patients with GC and PC. Primary endpoint was the rate of macroscopic complete remission (mCR) of PC at the time of second diagnostic laparoscopy/laparotomy prior to optional surgery.
Results
Median follow-up was 52 months. Out of 35 patients screened, 15 were allocated to arm A and 16 to arm B. mCR rate was 27% in arm A and 19% in arm B (p = 0.69). Severe side effects associated with catumaxomab were nausea, infection, abdominal pain, and elevated liver enzymes. Median progression-free (6.7 vs. 5.4 months, p = 0.71) and overall survival (13.2 vs. 13.0 months, p = 0.97) were not significantly different in both treatment arms.
Conclusions
Addition of catumaxomab to systemic chemotherapy was feasible and tolerable in advanced GC. Although the primary endpoint could not be demonstrated, results are promising for future investigations integrating intraperitoneal immunotherapy into a multimodal treatment strategy.
Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into cancer biology. Here we present a comprehensive analysis of genetic alterations in a pan-cancer cohort including 961 tumours from children, adolescents, and young adults, comprising 24 distinct molecular types of cancer. Using a standardized workflow, we identified marked differences in terms of mutation frequency and significantly mutated genes in comparison to previously analysed adult cancers. Genetic alterations in 149 putative cancer driver genes separate the tumours into two classes: small mutation and structural/copy-number variant (correlating with germline variants). Structural variants, hyperdiploidy, and chromothripsis are linked to TP53 mutation status and mutational signatures. Our data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
Zinc (Zn2+) can modulate platelet and coagulation activation pathways, including fibrin formation. Here, we studied the (patho)physiological consequences of abnormal platelet Zn2+ storage and release. To visualize Zn2+ storage in human and mouse platelets, the Zn2+ specific fluorescent dye FluoZin3 was used. In resting platelets, the dye transiently accumulated into distinct cytosolic puncta, which were lost upon platelet activation. Platelets isolated from Unc13d−/− mice, characterized by combined defects of α/δ granular release, showed a markedly impaired Zn2+ release upon activation. Platelets from Nbeal2−/− mice mimicking Gray platelet syndrome (GPS), characterized by primarily loss of the α-granule content, had strongly reduced Zn2+ levels, which was also confirmed in primary megakaryocytes. In human platelets isolated from patients with GPS, Hermansky-Pudlak Syndrome (HPS) and Storage Pool Disease (SPD) altered Zn2+ homeostasis was detected. In turbidity and flow based assays, platelet-dependent fibrin formation was impaired in both Nbeal2−/− and Unc13d−/− mice, and the impairment could be partially restored by extracellular Zn2+. Altogether, we conclude that the release of ionic Zn2+ store from secretory granules upon platelet activation contributes to the procoagulant role of Zn2+ in platelet-dependent fibrin formation.
The NEDD8-activating enzyme (NAE) inhibitor MLN4924 inhibits cullin-RING ubiquitin ligase complexes including the SKP1-cullin-F-box E3 ligase βTrCP. MLN4924 therefore inhibits also the βTrCP-dependent activation of the classical and the alternative NFĸB pathway. In this work, we found that a subgroup of multiple myeloma cell lines (e.g., RPMI-8226, MM.1S, KMS-12BM) and about half of the primary myeloma samples tested are sensitized to TNF-induced cell death by MLN4924. This correlated with MLN4924-mediated inhibition of TNF-induced activation of the classical NFκB pathway and reduced the efficacy of TNF-induced TNFR1 signaling complex formation. Interestingly, binding studies revealed a straightforward correlation between cell surface TNFR1 expression in multiple myeloma cell lines and their sensitivity for MLN4924/TNF-induced cell death. The cell surface expression levels of TNFR1 in the investigated MM cell lines largely correlated with TNFR1 mRNA expression. This suggests that the variable levels of cell surface expression of TNFR1 in myeloma cell lines are decisive for TNF/MLN4924 sensitivity. Indeed, introduction of TNFR1 into TNFR1-negative TNF/MLN4924-resistant KMS-11BM cells, was sufficient to sensitize this cell line for TNF/MLN4924-induced cell death. Thus, MLN4924 might be especially effective in myeloma patients with TNFR1+ myeloma cells and a TNFhigh tumor microenvironment.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes a significant burden on Westernized regions. The Western diet, high in salt intake, significantly contributes to disease development. However, there are a lack of data on salt literacy and salt intake among MASLD patients in Germany. Our study aims to analyze daily salt intake and salt-intake-related behavior in MASLD patients. Methods: 234 MASLD patients were prospectively included. Daily salt intake and salt-intake-related behavior were assessed via a food frequency questionnaire (FFQ—DEGS) and a salt questionnaire (SINU). Statistical analyses were performed using SPSS. Results: Mean daily salt intake was higher in men than in women (7.3 ± 5 g/d vs. 5.3 ± 4 g/d; p < 0.001). There was significant agreement between increased daily salt intake (6 g/d) and the behavioral salt index (SI) (p < 0.001). Men exhibited higher SI scores compared to women, indicating lower awareness of salt in everyday life. Multivariate analysis identified specific salt-intake-related behaviors impacting daily salt consumption. Conclusions: Our study reveals a strong link between daily salt intake and salt-intake-related behavior, highlighting sex-specific differences in an MASLD cohort. To enhance patient care in high-cardiovascular-risk populations, specific behavioral approaches may be considered, including salt awareness, to improve adherence to lifestyle changes, particularly in male patients.
Multiple myeloma (MM) frequently induces persisting osteolytic manifestations despite hematologic treatment response. This study aimed to establish a biometrically valid study endpoint for bone remineralization through quantitative and qualitative analyses in sequential CT scans. Twenty patients (seven women, 58 ± 8 years) with newly diagnosed MM received standardized induction therapy comprising the anti-SLAMF7 antibody elotuzumab, carfilzomib, lenalidomide, and dexamethasone (E-KRd). All patients underwent whole-body low-dose CT scans before and after six cycles of E-KRd. Two radiologists independently recorded osteolytic lesion sizes, as well as the presence of cortical destruction, pathologic fractures, rim and trabecular sclerosis. Bland–Altman analyses and Krippendorff’s α were employed to assess inter-reader reliability, which was high for lesion size measurement (standard error 1.2 mm) and all qualitative criteria assessed (α ≥ 0.74). After six cycles of E-KRd induction, osteolytic lesion size decreased by 22% (p < 0.001). While lesion size response did not correlate with the initial lesion size at baseline imaging (Pearson’s r = 0.144), logistic regression analysis revealed that the majority of responding osteolyses exhibited trabecular sclerosis (p < 0.001). The sum of osteolytic lesion sizes on sequential CT scans defines a reliable study endpoint to characterize bone remineralization. Patient level response is strongly associated with the presence of trabecular sclerosis.